SEC Tracker
Get the app

Syndax Pharmaceuticals SNDX

Syndax Pharmaceuticals FY 2020: revenue $1.5M; diluted EPS −$1.87

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Syndax Pharmaceuticals reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$1.5MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$73.2MNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS−$1.87No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$115.2MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  5. Cash from operations−$71.3MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Syndax Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Nurix Therapeutics NRIX public float $808M, May 30, 2025
  2. Niagen Bioscience NAGE public float $814M, Jun 30, 2025
  3. Cogent Biosciences COGT public float $773M, Jun 30, 2025
  4. uniQure QURE public float $765M, Jun 30, 2025
  5. Phibro Animal Health PAHC public float $764M, Dec 31, 2025